223 related articles for article (PubMed ID: 29369382)
1. Rituximab in myasthenia gravis: a "to be or not to be" inhibitor of T cell function.
Marino M; Bartoccioni E; Alboini PE; Evoli A
Ann N Y Acad Sci; 2018 Feb; 1413(1):41-48. PubMed ID: 29369382
[TBL] [Abstract][Full Text] [Related]
2. Use and monitoring of low dose rituximab in myasthenia gravis.
Blum S; Gillis D; Brown H; Boyle R; Henderson R; Heyworth-Smith D; Hogan P; Kubler P; Lander C; Limberg N; Pillans P; Prain K; Staples C; Walsh M; McCombe P; Wong R
J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):659-63. PubMed ID: 21071753
[TBL] [Abstract][Full Text] [Related]
3. Memory B cell resurgence requires repeated rituximab in myasthenia gravis.
Muto K; Matsui N; Unai Y; Sakai W; Haji S; Udaka K; Miki H; Furukawa T; Abe M; Kaji R
Neuromuscul Disord; 2017 Oct; 27(10):918-922. PubMed ID: 28694074
[TBL] [Abstract][Full Text] [Related]
4. Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis.
Jing S; Song Y; Song J; Pang S; Quan C; Zhou L; Huang Y; Lu J; Xi J; Zhao C
J Neuroimmunol; 2017 Oct; 311():14-21. PubMed ID: 28789841
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.
Iorio R; Damato V; Alboini PE; Evoli A
J Neurol; 2015 May; 262(5):1115-9. PubMed ID: 25308632
[TBL] [Abstract][Full Text] [Related]
6. Rituximab in AChR subtype of myasthenia gravis: systematic review.
Di Stefano V; Lupica A; Rispoli MG; Di Muzio A; Brighina F; Rodolico C
J Neurol Neurosurg Psychiatry; 2020 Apr; 91(4):392-395. PubMed ID: 32098874
[TBL] [Abstract][Full Text] [Related]
7. Dampening of CD8+ T Cell Response by B Cell Depletion Therapy in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Néel A; Bucchia M; Néel M; Tilly G; Caristan A; Yap M; Rimbert M; Bruneau S; Cadoux M; Agard C; Hourmant M; Godmer P; Brouard S; Bressollette C; Hamidou M; Josien R; Fakhouri F; Degauque N
Arthritis Rheumatol; 2019 Apr; 71(4):641-650. PubMed ID: 30375745
[TBL] [Abstract][Full Text] [Related]
8. Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis.
Jing S; Lu J; Song J; Luo S; Zhou L; Quan C; Xi J; Zhao C
J Neuroimmunol; 2019 Jul; 332():216-223. PubMed ID: 31100692
[TBL] [Abstract][Full Text] [Related]
9. Rituximab treatment of myasthenia gravis: A systematic review.
Tandan R; Hehir MK; Waheed W; Howard DB
Muscle Nerve; 2017 Aug; 56(2):185-196. PubMed ID: 28164324
[TBL] [Abstract][Full Text] [Related]
10. Low-dose rituximab treatment for new-onset generalized myasthenia gravis.
Li H; Huang Z; Jia D; Xue H; Pan J; Zhang M; Shi K; Shi FD; Zhang C
J Neuroimmunol; 2021 May; 354():577528. PubMed ID: 33662696
[TBL] [Abstract][Full Text] [Related]
11. [Proposal for rituximab treatment in patients with myasthenia gravis].
Konno S
Rinsho Shinkeigaku; 2013; 53(11):1312-4. PubMed ID: 24291971
[TBL] [Abstract][Full Text] [Related]
12. 10-year-outcomes after rituximab for myasthenia gravis: Efficacy, safety, costs of inhospital care, and impact on childbearing potential.
Stieglbauer K; Pichler R; Topakian R
J Neurol Sci; 2017 Apr; 375():241-244. PubMed ID: 28320139
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.
Landon-Cardinal O; Friedman D; Guiguet M; Laforêt P; Heming N; Salort-Campana E; Jouen F; Allenbach Y; Boyer O; Chatenoud L; Eymard B; Sharshar T; Benveniste O
J Neuromuscul Dis; 2018; 5(2):241-249. PubMed ID: 29865089
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis.
Li T; Zhang GQ; Li Y; Dong SA; Wang N; Yi M; Qi Y; Zhai H; Yang L; Shi FD; Yang CS
J Clin Neurosci; 2021 Mar; 85():6-12. PubMed ID: 33581791
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for myasthenia gravis: three case reports and review of the literature.
Stieglbauer K; Topakian R; Schäffer V; Aichner FT
J Neurol Sci; 2009 May; 280(1-2):120-2. PubMed ID: 19272616
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in refractory myasthenia gravis: Extended prospective study results.
Beecher G; Anderson D; Siddiqi ZA
Muscle Nerve; 2018 Sep; 58(3):452-455. PubMed ID: 29742795
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis.
Lebrun C; Bourg V; Bresch S; Cohen M; Rosenthal-Allieri MA; Desnuelle C; Ticchioni M
J Neuroimmunol; 2016 Sep; 298():79-81. PubMed ID: 27609279
[TBL] [Abstract][Full Text] [Related]
18. [Novel immunomodulatory therapies in myasthenia gravis].
Sukockiené E; Théaudin M; Loser V; Staedler K; Lalive PH; Lascano AM
Rev Med Suisse; 2024 Apr; 20(871):848-851. PubMed ID: 38665106
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.
Kamburova EG; Koenen HJ; van den Hoogen MW; Baas MC; Joosten I; Hilbrands LB
PLoS One; 2014; 9(11):e112658. PubMed ID: 25393622
[TBL] [Abstract][Full Text] [Related]
20. Potential utility of rituximab for Graves' orbitopathy.
Salvi M; Vannucchi G; Beck-Peccoz P
J Clin Endocrinol Metab; 2013 Nov; 98(11):4291-9. PubMed ID: 24009135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
